Similarly, being perceived as "fully compliant" rather than "fairly compliant" was associated with a relative mean % HbA 1c level that was 0.17 lower (CI -0.31 to -0.02). A significant predictor for the current regimen being any FDC (alone or in combination with one other OAD)
INTRODUCTION
There are currently more than 346 million individuals worldwide living with a diagnosis of diabetes, 90% of whom are diagnosed with type 2 diabetes mellitus (T2D).
1 By 2025 this figure is expected to have increased to 380 million individuals. 2 In Europe, the prevalence of T2D continues to rise. 3 Diabetes is a chronic, progressive disease that imposes a considerable physical, social, and emotional burden on individuals. It is associated with reduced life expectancy, significant morbidity due to specific diabetes-related microvascular complications, and an increased risk of macrovascular complications (ischemic heart disease, stroke, and peripheral vascular disease). [3] [4] [5] Diabetes is also associated with a considerable economic burden, mainly due to the cost of managing long-term complications of the disease. 6, 7 As there is currently no known cure for diabetes, management strategies aim to maintain good glycemic control and minimize the known risk factors for complications of the disease, including both microvascular and macrovascular complications. 8 However, despite the availability of effective antidiabetic medications, many patients with T2D do not achieve recommended targets for glycemic control. [9] [10] [11] [12] One factor that has been proposed as a potential factor in the failure to reach and maintain clinical targets among patients with T2D is failure to comply with or adhere or concord to their prescribed antidiabetic regimen. [15] [16] [17] [18] Compliance has been defined as the extent to which a patient acts in accordance with the physician's advice. 19 The term adherence is often used synonymously with the term compliance and refers to the extent to which a patient acts in accordance with the recommendations agreed with the physician.
Concordance implies the patient understands the recommendations. 19 In the current analysis, the authors have studied compliance with medication as observed by the physician.
Satisfaction with treatment may be associated with a patient's willingness or capacity to adhere to their prescribed medication regimen. 20 Indeed, recent guidelines recognize the need to take into account the willingness of patients to follow and engage positively with their prescribed medication. 21 Improved patient compliance has been associated with improved glycemic control. 
MATERIALS AND METHODS

Study Design
Data were drawn from the Adelphi Diabetes 
Patient Eligibility
Each participating physician completed a detailed patient record form (PRF) for the next six (PCPs) or nine (diabetologists/ endocrinologists) patients who consulted them and who were diagnosed with T2D and were receiving a noninsulin antidiabetic agent with or without insulin during the study period.
Participating physicians were also asked to invite all consecutive patients for whom they completed a PRF to complete a patient selfcompletion questionnaire (PSC). As stated above each patient provided consent for de-identified and aggregated reporting of research findings.
Data Collection
Physician Interviews
Following an initial screening call, physicians who agreed to participate in the study underwent a 1-hour face-to-face interview.
During the interview, information was collected about concomitant conditions, lifestyle, and current drug treatment of the patients with diabetes under their care.
PRFs (Physician Completed)
Each participating physician completed a Physicians were asked to ensure that all patients from the "random sample" group were given the opportunity to complete the questionnaires in private and to provide patients with an envelope in which to place their completed form and to seal the envelope before returning it to the physician. All responses were anonymized to maintain patient confidentiality.
Study Population
As noted, DSP data are derived from physician- 
RESULTS
A total of 641 physicians took part in the study (384 of whom were PCPs and 257 were specialists) and provided data for a total of 5891 patients (Table 1) . For the 4354 patients included in the random sample, 2179
were receiving care from a PCP and 2175
were receiving care from a diabetologist/ endocrinologist. The demographics and disease and treatment characteristics of the study population are summarized in Table 2 . The remaining five variables were associated with more likely to have been prescribed a (19) 438 (7) *Three patients were prescribed a DPP-4 in addition to a DPP-4/metformin FDC. †Includes alpha glucosidase inhibitors and thiazolidinedione/sulfonylurea FDC. ‡Includes regular insulin and insulin not further specified. BMI=body mass index; DPP-4=dipeptidyl peptidase-4 inhibitor; FDC=fixed-dose combination; GLP-1=glucagon-like peptide-1 agonist; OAD=oral antidiabetic; SD=standard deviation; SU=sulfonylurea; TZD=thiazolidinedione.
DPP-4 FDC versus a DPP-4 free-form combination.
These variables were physician perception of "poor compliance," "fairly compliant," or "fully compliant" versus "not at all compliant" for the patient; "improves compliance," or "covered by insurance" as reasons for physician choice of therapy; physician who indicated that they use FDCs frequently or as a first choice where possible; and physicians who "tend to agree," "agree," or "strongly agree" that they prescribe
FDCs to noncompliant patients. In Table 5 This analysis drew on data recorded in the PSCs, which were available for the random sample only as PSCs were not included in the oversample.
Responses relating to 562 patients who were receiving OADs alone and were not receiving insulin or other injectable antidiabetic agents were eligible for inclusion in this analysis. Of these, 155 (28%) were receiving an FDC alone or in combination with a single OAD, and 407 (72%)
were receiving OAD free-form combination therapy.
Those receiving an FDC had a mean satisfaction with treatment (DTSQ) score of 27.5 (SD±4.69), whilst those on free-form combination therapy had a mean DTSQ score of 26.0 (SD±5.47; P=0.0041). Table 3 . Physician-reported characteristics of patients comparing patients prescribed DPP-4 free-form combination versus a DPP-4 FDC (random sample and over-sample) for patients receiving dual or triple therapy (n=696; univariate analysis to confirm population eligible for the logistic regression analysis in Table 4 ). ‡The exact timing of the HbA 1c test in relation to the prescription of the DPP-4 FDC or DPP-4 free-form combination was not collected. Physicians completed one of three tick box responses (test conducted in the last 3 months, test conducted at some time in the period between 3 and 6 months, or test conducted in the last 6-12 months). However, the populations in the DPP-4 free form group and the population in the DPP-4 FDC group did not differ in their responses to the tick boxes. Therefore, while the information available relating to timing of the HbA 1c test is a limitation of the current analyses, the limitation applies equally to both groups of patients. §Source: patient record form, Section LQ1a -in your experience, how compliant is this patient with their diabetes treatment? Response options: not at all compliant, has poor compliance, fairly compliant, fully compliant. ||Source: physician interview.
DPP-4 free-form DPP-4 FDC
¶Source: physician interview. BMI=body mass index; DPP-4=dipeptidyl peptidase-4 inhibitor; FDC=fixed-dose combination; HbA 1c =glycated hemoglobin; SD=standard deviation.
The logistic regression analyses identified four more patient-focused covariates that were associated with an increased likelihood of receiving an FDC prescription, and four covariates that were associated with an increased likelihood of receiving an OAD freeform combination prescription (Table 6) Physician-related factors associated with DPP-4 FDC prescribing decisions were associated with a desire to improve patient compliance. 
